Despite the differences in the two models, with tumors forming in the mouse pancreas in the KPC model and tumor cells injected under the skin in the in vivo xenograft model, both studies provide evidence that the pancreatic cancer may only transiently be inhibited by a SMO antagonist, revealing that the challenge of overcoming resistance is ever present. The gene discussed is SMO; the disease is neoplasm.